ArticleMedComm2023

Long-term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine-plus-camrelizumab epi-immunotherapy and treatment cessation.

Chunmeng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.